(RTTNews) - Novocure (NVCR) announced the FDA approved new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Novocure ...
(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...
Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). This is ...
Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC). This is an ASCO Meeting Abstract from the 2015 ASCO ...
In this Article, we report a conformable ultrasound bladder patch (cUSB-Patch) that is mechanically adaptive and can provide the real-time in vivo monitoring of bladder volume (Fig. 1b,c and ...
Diagnostic ultrasound has become an invaluable imaging modality to healthcare professionals for the purpose of non-invasive examination of soft tissue, as it carries with it no associated risks of ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results